Tango posts 92% response rate in PDAC combo trial; raises $651M to fund Phase 3

Filed August 11, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~2 min read

Key Changes

• high

  Vopimetostat + daraxonrasib achieved 92% objective response rate in MTAP-deleted pancreatic cancer (11 of 12 patients) and 100% in NSCLC (3 of 3), with 90% six-month progression-free survival in PDAC; company plans Phase 3 randomized trial in front-line setting.

  MD&A: vopimetostat + daraxonrasib Phase 1/2 data verify on EDGAR →
• high

  Company deprioritized TNG260 (CoREST inhibitor) due to limited clinical benefit and halted TNG961 (HBS1L degrader) development, shutting down both trials to focus resources on the PRMT5 pipeline; direct R&D spend on TNG260 fell 26% and TNG961 fell 96% YoY.

  MD&A: TNG260 and TNG961 deprioritization verify on EDGAR →
• high

  Net loss for Q2 2026 was $55.3M (diluted EPS -$0.37), widening 42.4% from $38.8M in Q2 2025, driven by higher R&D spend on vopimetostat (up 121% to $12.3M) and near-doubling of G&A expense to $22.6M, while collaboration revenue fell to zero following Gilead research-term truncation in August 2025.

  MD&A: net loss verify on EDGAR →